Stock BLUE BLUEBIRD BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings bluebird bio, Inc.

Equities

BLUE

US09609G1004

Real-time Estimate Cboe BZX
Other stock markets
 03:43:26 2024-04-23 pm EDT 		5-day change 1st Jan Change
0.979 USD +2.66% Intraday chart for bluebird bio, Inc. -0.16% -28.36%
Mar. 27 Wells Fargo Trims Price Target on Bluebird Bio to $3 From $4, Maintains Equalweight Rating MT
Mar. 27 Wedbush Adjusts bluebird bio's PT to $1.72 From $1.68, Maintains Neutral Rating MT

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The company appears to be poorly valued given its net asset value.
  • For the past twelve months, EPS forecast has been revised upwards.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Analyst opinion has improved significantly over the past four months.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • One of the major weak points of the company is its financial situation.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
BLUEBIRD BIO, INC. Stock bluebird bio, Inc.
-28.36% 184M
C
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-0.21% 103B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+3.52% 96.73B
B+
ARGENX SE Stock argenx SE
+1.66% 21.31B
B
BIONTECH SE Stock BioNTech SE
-16.27% 21.21B
B+
GENMAB A/S Stock Genmab A/S
-6.82% 18.79B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.41% 16.37B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-22.93% 13.68B
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.72% 13.44B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+22.24% 10.98B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. BLUE Stock
  4. Ratings bluebird bio, Inc.